Erythropoietin

Erythropoietin is not a routine test. It is requested mainly to help distinguish between different types of polycythaemia or anaemia and to find out whether the amount of erythropoietin being produced is appropriate for the level of anaemia present. It is usually requested following abnormal findings on a full blood count (FBC), a group of tests that includes a RBC count and evaluation, a haemoglobin and a haematocrit. These tests establish the presence and severity of polycythaemia and/or anaemia and give the doctor clues as to the likely origin of the anaemia. Erythropoietin is requested either to differentiate which type of polycythaemia is present or to help determine if insufficient hormone may be causing and/or making worse the anaemia.

In patients with chronic kidney disease it may be used at intervals to test the kidneys' continued ability to produce sufficient erythropoietin. The erythropoietin test is not usually used as a monitoring tool for anaemia. This is done by following the RBC count, haemoglobin, haematocrit and reticulocyte count (a measurement of immature RBCs in the blood and an indicator of bone marrow function).

Occasionally, an erythropoietin test may be used to help find out if a disease that is causing an excess production of RBCs is due to an overproduction of erythropoietin.

An erythropoietin test may be requested when a patient has anaemia that does not appear to be caused by iron deficiency, vitamin B12 or folate deficiency, haemolysis or blood loss (such as gastrointestinal bleeding). It may be used when the patient's RBC count, haemoglobin and haematocrit are decreased and the reticulocyte count is normal or decreased (indicating that the bone marrow has not responded to the anaemia by increasing RBC production). It is used when the doctor is attempting to distinguish between a disease that is suppressing bone marrow function and an inadequate amount of erythropoietin. It is very useful when a patient has an excessive number of red blood cells to determine if the polycythaemia is erythropoietin dependent or independent.

In patients with chronic kidney disease erythropoietin levels may be used whenever a doctor suspects that kidney disease could be interfering with erythropoietin production.

In patients with too many RBCs, an erythropoietin level may be used during an investigation of the overproduction to see if increased erythropoietin concentrations are present.

If erythropoietin levels are increased and the patient is anaemic but not producing a sufficient number of new RBCs then the anaemia is likely to be related to a decrease in bone marrow function. If the patient is anaemic and erythropoietin levels are low or normal then the kidneys may not be producing an appropriate amount of the hormone.

If a patient has too many RBCs and erythropoietin levels are increased, then it is likely that excess erythropoietin is being produced - either by the kidneys or by other tissue in the body. If a patient has excess RBC production and erythropoietin levels are normal or low then it is likely that the polycythemia has a cause that is independent of erythropoietin production.

If a patient's anaemia is due to a vitamin B12, folate or iron deficiency then the anaemia may persist even when adequate amounts of erythropoietin are being created. The RBCs produced in these deficiencies may not be normal in size, shape and/or haemoglobin content. If the patient is producing an abnormal form of haemoglobin (such as may occur with thalassaemia or sickle cell disease) or has a bone marrow disorder then increased erythropoietin may not resolve the anaemia.

Erythropoietin stimulating agents (ESA) are synthetic forms of erythropoietin (recombinant human erythropoietin or rh-EPO) that have been developed to help increase RBC production in patients with chronic kidney disease and other anaemias related to bone marrow suppression and/or failure (such as that due to radiation or chemotherapy treatment for cancer). The drug treatment is given by intravenous or subcutaneous injection, and some forms e.g. darbopoietin alfa known as novel erythropoietin stimulating hormone (NESP) can be given less frequently.

The synthetic hormone's use has been promising, helping to decrease the need for blood transfusions and improving the quality life for many affected patients.

Doctors monitor red cell haemoglobin levels and prescribe only the amount of erythropoietin needed to stimulate the production of red cells to avoid blood transfusions. If some patients are given higher than recommended doses they run an increased risk of developing blood clots, heart attacks, strokes and death. Also, certain cancer patients may experience a growth in tumour size.

The same synthetic erythropoietin is also being used by some athletes as a form of “blood doping.” Those who use it are trying to increase their endurance and oxygen capacity by increasing the number of RBCs in their bloodstream. This use of the drug can be dangerous, resulting in hypertension and increasing the viscosity (thickness) of the blood. Its use has been prohibited by most sports organisations including the International Association of Athletics Federations, and erythropoietin is now being tested for as part of the Olympics anti-doping programme. This test is a urine test and determines how much of the synthetic form is present.

Not directly. If an insufficiency is due to a temporary kidney condition then it may improve as the condition get better. In many cases, however, the decreased erythropoietin production is due to chronic kidney disease and will not get better over time. When there is a known insufficiency the doctor will work with the patient to address and minimise the affects of the resulting anaemia and may treat the patient with synthetic erythropoietin.